Adaptin Bio (APTN) Liabilities and Shareholders Equity (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $706117.0 in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 75.26% year-over-year to $706117.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 28.23% YoY), and the FY2025 full-year result was $619159.0, up 158.61% from the prior year.
• Liabilities and Shareholders Equity improved to $706117.0 in Q1 2026, from $619159.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 million in Q1 2025 to a low of $322.0 in Q2 2024.
• A 5-year average of $588590.7 and a median of $119957.5 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 750953.68% in 2025 and plunged 75.26% in 2026, its largest moves.
• Tracing APTN's Liabilities and Shareholders Equity over 5 years: stood at $500.0 in 2022, then retreated by 24.0% to $380.0 in 2023, then jumped by 62903.95% to $239415.0 in 2024, then surged by 158.61% to $619159.0 in 2025, then advanced by 14.04% to $706117.0 in 2026.
• Business Quant data shows APTN's Liabilities and Shareholders Equity at $706117.0 in Q1 2026, $619159.0 in Q4 2025, and $979474.0 in Q3 2025.